Puymirat Etienne, Didier Romain, Eltchaninoff Hélène, Lung Bernard, Collet Jean-Philippe, Himbert Dominique, Durand Eric, Leguerrier Alain, Leprince Pascal, Fajadet Jean, Teiger Emmanuel, Chevreul Karine, Lièvre Michel, Tchetché Didier, Leclercq Florence, Chassaing Stéphan, Le Breton Hervé, Donzeau-Gouge Patrick, Lefèvre Thierry, Carrié Didier, Gillard Martine, Blanchard Didier
Department of Cardiology, European Hospital of Georges Pompidou, Public Assistance Hospitals of Paris, Paris Descartes University, Paris, France.
Department of Cardiology, Brest University Hospital, Brest, France.
Clin Cardiol. 2017 Dec;40(12):1316-1322. doi: 10.1002/clc.22830. Epub 2017 Dec 16.
Coronary artery disease (CAD) is common in patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of CAD distribution before TAVR on short- and long-term prognosis remains unclear.
We hypothesized that the long-term clinical impact differs according to CAD distribution in patients undergoing TAVR using the FRench Aortic National CoreValve and Edwards (FRANCE-2) registry.
FRANCE-2 is a national French registry including all consecutive TAVR performed between 2010 and 2012 in 34 centers. Three-year mortality was assessed in relation to CAD status. CAD was defined as at least 1 coronary stenosis >50%.
A total of 4201 patients were enrolled in the registry. For the present analysis, we excluded patients with a history of coronary artery bypass. CAD was reported in 1252 patients (30%). Half of the patients presented with coronary multivessel disease. CAD extent was associated with an increase in cardiovascular risk profile and in logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) (from 19.3% ± 12.8% to 21.9% ± 13.5%, P < 0.001). Mortality at 30 days and 3 years was 9% and 44%, respectively, in the overall population. In multivariate analyses, neither the presence nor the extent of CAD was associated with mortality at 3 years (presence of CAD, hazard ratio [HR]: 0.90; 95% confidence interval [CI]: 0.78-1.07). A significant lesion of the left anterior descending (LAD) was associated with higher 3-year mortality (HR: 1.42; 95% CI: 1.10-1.87).
CAD is not associated with decreased short- and long-term survival in patients undergoing TAVR. The potential deleterious effect of LAD disease on long-term survival and the need for revascularization before or at the time of TAVR should be validated in a randomized control trial.
冠状动脉疾病(CAD)在接受经导管主动脉瓣置换术(TAVR)的患者中很常见。然而,TAVR术前CAD分布对短期和长期预后的影响仍不清楚。
我们假设,使用法国主动脉国家核心瓣膜和爱德华兹(FRANCE-2)注册研究,接受TAVR的患者中,CAD分布的长期临床影响有所不同。
FRANCE-2是一项法国全国性注册研究,纳入了2010年至2012年期间在34个中心连续进行的所有TAVR手术。根据CAD状态评估三年死亡率。CAD定义为至少1处冠状动脉狭窄>50%。
共有4201例患者纳入该注册研究。在本次分析中,我们排除了有冠状动脉搭桥手术史的患者。1252例患者(30%)报告有CAD。半数患者表现为冠状动脉多支病变。CAD程度与心血管风险特征增加以及逻辑欧洲心脏手术风险评估系统(EuroSCORE)增加相关(从19.3%±12.8%增至21.9%±13.5%,P<0.001)。总体人群中30天和3年死亡率分别为9%和44%。在多变量分析中,CAD的存在与否及程度均与3年死亡率无关(CAD存在,风险比[HR]:0.90;95%置信区间[CI]:0.78-1.07)。左前降支(LAD)的显著病变与较高的3年死亡率相关(HR:1.42;95%CI:1.10-1.87)。
CAD与接受TAVR患者的短期和长期生存率降低无关。LAD疾病对长期生存的潜在有害影响以及TAVR术前或术时血运重建的必要性应在随机对照试验中得到验证。